Norris Perne & French LLP Ocuphire Pharma, Inc. Call Options Transaction History
Norris Perne & French LLP
- $1.36 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCUP
# of Institutions
42Shares Held
2.55MCall Options Held
14.1KPut Options Held
800-
Vanguard Group Inc Valley Forge, PA992KShares$1.05 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$288,6170.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX166KShares$175,6960.0% of portfolio
-
Richmond Brothers, Inc. Jackson, MI156KShares$164,9570.13% of portfolio
-
Black Rock Inc. New York, NY107KShares$113,3510.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $21.8M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...